Recombinant Human Anti-EGFR Antibody (Nimotuzumab) (CAT#: PABX-052)

Anti-EGFR antibody is a Humanized antibody of IgG class that binds to an EGFR.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Tested Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
IB

Figure 1 Binding of nimotuzumab, cetuximab and their monovalent fragments to human tumor cell lines with different EGFR expression.

Figure 1 Binding of nimotuzumab, cetuximab and their monovalent fragments to human tumor cell lines with different EGFR expression.

(A) Immunoblot for the total EGFR and actin were performed for the indicated tumor cells.

Garrido, G., Tikhomirov, I. A., Rabasa, A., Yang, E., Gracia, E., Iznaga, N., ... & Pérez, R. (2011). Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer biology & therapy, 11(4), 373-382.

FC

Figure 2 Binding of nimotuzumab, cetuximab and their monovalent fragments to human tumor cell lines with different EGFR expression.

Figure 2 Binding of nimotuzumab, cetuximab and their monovalent fragments to human tumor cell lines with different EGFR expression.

(B) Tumor cells (grey histograms) were stained with an anti-EGFR antibody (black histograms), followed by incubation with FITC-conjugated rabbit anti-rat IgG-H&L.

Garrido, G., Tikhomirov, I. A., Rabasa, A., Yang, E., Gracia, E., Iznaga, N., ... & Pérez, R. (2011). Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer biology & therapy, 11(4), 373-382.

SPR

Figure 3 Examination of cetuximab and nimotuzumab binding kinetics using surface plasmon resonance.

Figure 3 Examination of cetuximab and nimotuzumab binding kinetics using surface plasmon resonance.

(B) Under bivalent binding conditions (intended to represent binding to cells with high EGFR expression), antibodies behaved similarly and accumulated to the equivalent levels; ligand-FcEGFR chimera (dimer); analyte-100 nM anti-EGFR antibodies. Experiments were performed three times with similar results. Representative data are shown.

Garrido, G., Tikhomirov, I. A., Rabasa, A., Yang, E., Gracia, E., Iznaga, N., ... & Pérez, R. (2011). Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer biology & therapy, 11(4), 373-382.

Apop

Figure 4 In vitro effects of nimotuzumab and cetuximab on cells with different EGFR expression levels.

Figure 4 In vitro effects of nimotuzumab and cetuximab on cells with different EGFR expression levels.

(B) Cells treated with antibodies (70 nM) or their monovalent Fab fragments (140 nM) for 24 h were fixed with ice-cold methanol/acetone and stained with PI (400 μg/ml). The percentage of cells with DNA fragmentation (apoptotic cells) was analyzed by flow cytometry. For both experiments the U1906 cell line was used as a negative control for EGFR expression and the fenritenide was used as positive control in the apoptosis assay (data not shown). One representative experiment out of three is shown in each case.

Garrido, G., Tikhomirov, I. A., Rabasa, A., Yang, E., Gracia, E., Iznaga, N., ... & Pérez, R. (2011). Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer biology & therapy, 11(4), 373-382.

ELISA

Figure 5 Competition experiments performed for Nimotuzumab.

Figure 5 Competition experiments performed for Nimotuzumab.

A, ELISA plates were coated with 5 μg/mL eEGFR and incubated with different mixtures containing a constant concentration of biotinylated Nimotuzumab Fab fragment and decreasing concentrations of the Cetuximab Fab fragment. OD, optical density.

Talavera, A., Friemann, R., Gómez-Puerta, S., Martinez-Fleites, C., Garrido, G., Rabasa, A., ... & Krengel, U. (2009). Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer research, 69(14), 5851-5859.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Human
  • Derivation
  • Human
  • Type
  • IgG
  • Specificity
  • Tested positive against native Human EGFR
  • Species Reactivity
  • Human
  • Clone
  • Nimotuzumab
  • Applications
  • WB, ELISA, FuncS, IB, FC, SPR, Apop

Product Property

  • Purity
  • >95% by SDS-PAGE and HPLC analysis
  • Storage
  • Store the antibody (in aliquots) at -20°C. Avoid repeated freezing and thawing of samples.

Applications

  • Application Notes
  • The EGFR antibody has been reported in applications of Western Blot, Enzyme-linked Immunosorbent Assay, Functional Assay, Immunoblotting, Flow Cytometry, Surface Plasmon Resonance, Apoptosis.

Target

  • Alternative Names
  • EGFR; epidermal growth factor receptor; ERBB; HER1; mENA; ERBB1; PIG61; NISBD2; proto-oncogene c-ErbB-1; cell growth inhibiting protein 40; erb-b2 receptor tyrosine kinase 1; cell proliferation-inducing protein 61; receptor tyrosine-protein kinase erbB-1; avian erythroblastic leukemia viral (v-erb-b) oncogene homolog; mAb806; LICR 806; ABT-806; ch806

Related Resources

  • Biosimilar Overview
  • Related Diseases
  • Related Signaling Pathways
Please refer to Nimotuzumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Nimotuzumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone Nimotuzumab"

See other products for "EGFR"

Chimeric Antibody

CAT Product Name Application Type
TAB-0225CL-F(E) Human Anti-EGFR Recombinant Antibody; Fab Fragment (TAB-0225CL-F(E)) Block, Inhib, FuncS, Apop, In vivo Chimeric (Mouse/Human) Fab
TAB-272MZ Human Anti-EGFR Recombinant Antibody (TAB-272MZ) FuncS Chimeric (mouse/human) IgG
TAB-302MZ Human Anti-EGFR Recombinant Antibody (TAB-302MZ) ELISA Chimeric (mouse/human) IgG1
TAB-308MZ Human Anti-EGFR Recombinant Antibody (TAB-308MZ) FuncS Chimeric antibody (mouse/human)
TAB-272MZ-S(P) Mouse Anti-EGFR Recombinant Antibody; scFv Fragment (TAB-272MZ-S(P)) FuncS Mouse scFv

Fc Glycosylation

High-mannose Glycoform

CAT Product Name Application Type
Gly-055LC-1 Recombinant Anti-Human EGFR Antibody (Fc glycosylation/High-mannose glycosylated) ELISA Chimeric antibody (mouse/human)

Deglycosylated Antibody (Non-glycosylated IgGs)

CAT Product Name Application Type
Gly-167LC Recombinant Anti-Human EGFR Antibody (Non-glycosylated) ELISA Human antibody

Chicken IgY Antibody

CAT Product Name Application Type
BRD-0183MZ Chicken Anti-EGFR Polyclonal IgY WB Chicken antibody
BRD-0668MZ Chicken Anti-EGFR Polyclonal IgY WB Chicken antibody

Neutralizing Antibody

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-165 Afuco™ Anti-EGFR ADCC Recombinant Antibody (Matuzumab), ADCC Enhanced Neut, ELISA, IF, IP, FuncS, FC ADCC enhanced antibody
AFC-TAB-464CQ Afuco™ Anti-EGFR ADCC Recombinant Antibody (Tomuzotuximab), ADCC Enhanced ELISA, IHC, FC, IP, IF, FuncS ADCC enhanced antibody
AFC-TAB-003 Afuco™ Anti-EGFR ADCC Recombinant Antibody (Cetuximab), ADCC Enhanced IF, IP, Neut, FuncS, ELISA, FC ADCC enhanced antibody
AFC-TAB-040 Afuco™ Anti-EGFR ADCC Recombinant Antibody (Zalutumumab), ADCC Enhanced ELISA, FC, IP, FuncS, IF, Neut ADCC enhanced antibody
AFC-TAB-119 Afuco™ Anti-EGFR ADCC Recombinant Antibody (Necitumumab), ADCC Enhanced FC, IP, ELISA, Neut, FuncS, IF ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for PABX-052. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare